Search

Displaying results 1341 - 1350 of 8195 in total
  1. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins

  2. Drug

    Salmon calcitonin

    go.drugbank.com/drugs/DB00017
    ApprovedInvestigational

    Synthetic peptide, 32 residues long formulated as a nasal spray.

    Products: Miacalcin Nasal Spray 200 Iu, MIACALCIC INJECTION 50 iu/ml
  3. Drug

    Isoprenaline

    go.drugbank.com/drugs/DB01064
    ApprovedInvestigational

    Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, a...

    Mixtures: Duo-Medihaler
  4. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  5. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    Ferric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.

  6. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.

    Categories: P-glycoprotein substrates
  7. Drug

    PF-5190457

    go.drugbank.com/drugs/DB14870
    Investigational

    PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).

  8. Drug

    Resorcinol

    go.drugbank.com/drugs/DB11085
    ApprovedInvestigational

    It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses

    Mixtures: DG Health Feminine Anti-itch
  9. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    This drug is unique from others in this class due to its rapid onset of effects and short duration of action. … [A257153] Midazolam is considered a schedule IV drug in the United States due to the low potential for abuse and low risk of dependence.[L5074]

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.